Dermatology · Chapel Hill, NC
NPI
1225265903
Since 2009
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
101 Manning Dr, Department of Internal Medicine
Chapel Hill, NC, 27514
Phone (919) 966-1072
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
714 services
Medicare patients, 2024
135
Average age 62
Drug cost, 2024
$5.2M
1,172 prescriptions
Company payments, 2025
$157K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher J Sayed was code 17003 (destruction skin lesion), 220 times for 30 patients. In total Christopher J Sayed billed 714 services in 40 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 220 | 30 | $4.33 | $952 |
| 99214 Office E&M - Established | Office | 118 | 78 | $79.48 | $9,378 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 75 | 15 | $0.72 | $53.75 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 58 | 44 | $11.49 | $666 |
| 99213 Office E&M - Established | Office | 56 | 46 | $54.82 | $3,070 |
| 17000 Destruction Skin Lesion | Office | 50 | 34 | $30.46 | $1,523 |
| 17110 Destruction Skin Lesion | Office | 27 | 24 | $63.98 | $1,727 |
| 11102 Skin Biopsy | Office | 14 | 12 | $65.42 | $916 |
| 11900 Skin | Office | 14 | 14 | $33.32 | $466 |
By year: 2022 $35K for 617 services; 2023 $27K for 494 services; 2024 $29K for 714 services.
Medicare prescription drug claims, 2024
In 2024, the drug Christopher J Sayed prescribed most often to Medicare patients was Cosentyx Unoready Pen (Secukinumab), with 87 prescriptions and refills. In total Christopher J Sayed wrote 1,172 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cosentyx Unoready Pen Secukinumab | 87 | 90 | 18 | $1.1M |
| Humira(Cf) Pen Adalimumab | 86 | 86 | 13 | $1.5M |
| Methotrexate Methotrexate Sodium | 58 | 104 | 15 | $368 |
| Doxycycline Hyclate Generic | 49 | 49 | 11 | $1,906 |
| Triamcinolone Acetonide Generic | 49 | 51 | 31 | $513 |
| Ertapenem Ertapenem Sodium | 49 | 49 | Under 11 | $18K |
| Remicade Infliximab | 47 | 50 | Under 11 | $700K |
| Prednisone Generic | 46 | 53 | 14 | $387 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 43 | 43 | 13 | $1,410 |
| Cefdinir Generic | 37 | 43 | 12 | $2,343 |
| Clindamycin Hcl Generic | 37 | 41 | Under 11 | $1,109 |
| Clobetasol Propionate Generic | 30 | 30 | 17 | $1,459 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 28 | 28 | Under 11 | $309 |
| Inflectra Infliximab-Dyyb | 23 | 25 | Under 11 | $175K |
| Fluconazole Generic | 21 | 23 | 12 | $492 |
Brand drugs: 374 claims; generic drugs: 798 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher J Sayed $157K ($155K in general payments such as food, travel and fees and $1,200 for research) from 10 companies. The largest payer was Abbvie Inc. with $112K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 63 | $112K |
| UCB, Inc. UCB.BR | 10 | $18K |
| Ucb Sa UCB.BR | 5 | $13K |
| Sanofi-Aventis U.S. LLC SNY | 1 | $5,322 |
| Incyte Corporation INCY | 2 | $4,875 |
| UCB Biosciences Inc. UCB.BR | 1 | $2,000 |
| Novartis Pharma AG NVS | 1 | $1,200 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $73.5 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.